11 completed, 3 terminated, 2 unknown, 1 active not recruiting. 9 Phase 2, 5 Phase 1, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Unknown 2, Terminated 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Myrexis Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS) - Prostate Cancer | Not applicable | Active not recruiting | University of Michigan Rogel Cancer Center | 805 | 2020-11-05 | 2026-09-09 |
| Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme Verubulin, Temozolomide & Radiation Therapy - Glioblastoma Multiforme | Phase 2 | Completed | Myrexis Inc. | 5 | 2010-12-01 | 2012-04-11 |
| A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs - HIV Infections | Phase 2 | Terminated | Myrexis Inc. | 2 | 2009-11-01 | 2010-06-14 |
| Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments MPC-3100 (an Hsp90 inhibitor) - Cancer | Phase 1 | Completed | Myrexis Inc. | 26 | 2009-06-01 | 2011-10-14 |
| Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme Azixa - Glioblastoma Multiforme | Phase 2 | Completed | Myrexis Inc. | 56 | 2009-04-01 | 2011-10-14 |
| A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days Bevirimat - HIV-1 Infection | Phase 2 | Completed | Myrexis Inc. | 35 | 2008-11-01 | 2010-04-01 |
| Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection. bevirimat dimeglumine - HIV Infections | Phase 2 | Completed | Myrexis Inc. | 32 | 2008-05-01 | 2010-01-06 |
| Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma MPC-6827 + Temozolomide - Metastatic Melanoma | Phase 1 / Phase 2 | Completed | Myrexis Inc. | 22 | 2008-03-01 | 2010-08-23 |
| Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme MPC-6827 + Carboplatin - Glioblastoma Multiforme | Phase 1 / Phase 2 | Unknown | Myrexis Inc. | 30 | 2008-03-01 | 2011-03-25 |
| Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine Phlebotomy - Breast Cancer | Completed | M.D. Anderson Cancer Center | 102 | 2007-05-23 | 2017-05-08 | |
| Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol MPC-7869 - Alzheimer's Disease | Phase 3 | Terminated | Myrexis Inc. | 1000 | 2006-09-01 | 2008-08-05 |
| Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's MPC-7869 - Alzheimer Disease, Dementia | Phase 3 | Terminated | Myrexis Inc. | 800 | 2006-05-01 | 2008-08-05 |
| Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks* matching placebo, Bevirimat - HIV Infections | Phase 2 | Completed | Myrexis Inc. | 92 | 2006-04-01 | 2010-01-20 |
| Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases MPC-6827 - Brain Neoplasms | Phase 1 | Completed | Myrexis Inc. | 18 | 2005-12-01 | 2008-02-13 |
| Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors MPC-6827 - Refractory Solid Tumors | Phase 1 | Completed | Myrexis Inc. | 48 | 2005-03-01 | 2008-02-13 |
| Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's MPC-7869 - Alzheimer Disease, Dementia | Phase 3 | Completed | Myrexis Inc. | 1600 | 2005-02-01 | 2009-05-05 |
| R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence tarenflurbil, adjuvant therapy - Prostate Cancer | Phase 2 | Unknown | Myrexis Inc. | 2002-02-01 | 2013-12-18 |
Alzheimer Disease (3) · Brain Neoplasms (3) · Dementia (3) · Glioblastoma (3) · HIV Infections (3) · Acquired Immunodeficiency Syndrome (2) · Neoplasm Metastasis (2) · Prostatic Neoplasms (2) · Recurrence (2) · Breast Neoplasms (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1) · Melanoma (1)
verubulin (6) · bevirimat (4) · tarenflurbil (4) · Temozolomide (2) · 1-(4-(2-(6-amino-8-((6-bromo-1,3-benzodioxol-5-yl)sulfanyl)-9H-purin-9-yl)ethyl)piperidin-1-yl)-2-hydroxypropan-1-one (1) · Carboplatin (1) · Chemotherapy, Adjuvant (1) · Phlebotomy (1) · Radiotherapy (1) · Standard of Care (1)
United States (16) · Canada (3) · Australia (1) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Andrew Beelen, MD (6) · Andrew P. Beelen, MD (2) · Margaret Yu, MD (2) · Mark Laughlin, MD (2) · Andrew Beelen, M.D. (1) · Calvin J Cohen, MD, MSc (1) · Daniel Spratt, M.D. (1) · Ed Swabb, MD (1) · Gary J Richmond, MD, PA (1) · Jacob P Lalezari, MD (1) · Lawrence Recht, MD (1) · Melanie A Thompson, MD (1) · Sheron B. Bass, RN, MS (1) · Todd Morgan, M.D. (1) · Vicente Valero, MD (1)
R01CA240991 (1)